Oncotype DX AR-V7 Nucleus Detect Test AR-V7 ADVOCATE TOOLKIT

Transcription

1 Oncotype DX AR-V7 Nucleus Detect Test AR-V7 ADVOCATE TOOLKIT or

2 Advocate TOOLKIT We re pleased to be able to share these AR-V7 resources with you video, graphics, social media templates, and blog. Feel free to take these materials and modify as you feel appropriate for your audiences. If you have any questions or would like additional resources, please do not hesitate to let us know! Bernadette and Sara

3 Video Click on the YouTube video below to watch and share on your favorite social media platforms. What is the Oncotype DX AR-V7 Nucleus Detect Test

4 Graphics Click to download the graphics below and use on your favorite social media platforms.

5 Social Media Feel free to edit and use these sample posts and share on your social media channels. Did you know a simple blood test can help you find the best treatment for your #metastatic castration-resistant #prostatecancer? Find out more at bit.ly/odxarv7 Did you know #prostatecancer patients can become resistant to hormone therapies over time? The #Oncotype DX AR-V7 Nucleus Detect test can help you and your doctor determine the treatment that s best for you. Check out this video: youtu.be/mouxuoku4bi DYK: AR-V7 (+) status in #metastatic castration-resistant #prostatecancer indicates more aggressive cancers and that patients may benefit more from chemotherapy. Learn more at bit.ly/odxarv7 DYK: AR-V7 (-) status in #metastatic castration-resistant #prostatecancer indicates patients may have more benefit from new/additional anti-androgen therapy. Learn more at bit.ly/odxarv7 #Metastatic castration-resistant #prostatecancer now have tools to help determine the best treatment option for them. Find out more about the #Oncotype DX AR-V7 Nucleus Detect test youtu.be/mouxuoku4bi

6 Blog Feel free to share the information from the sample blog to create your own blog, newsletter article or online feature. For men with metastatic castration resistant prostate cancer (mcrpc), deciding between treatment options can be complicated. A number of therapies are now available for these patients, including androgen receptor (AR)-targeted drugs as well as chemotherapy, but knowing which treatment will provide the most benefit to which patient has been a challenge. However, with the recent availability of the Oncotype DX AR-V7 Nucleus Detect test, men with mcrpc now can get more clarity. Today, mcrpc patients are often first treated with AR-targeted drugs such as XTANDI or ZYTIGA ¹. Unfortunately, over time, many patients acquire resistance, meaning they will no longer receive benefit from the drug and need to consider another treatment. Traditionally, it s been difficult to predict what type of treatment will be better for an individual patient do you go to another AR-drug or switch to chemotherapy? With the Oncotype DX AR-V7 Nucleus Detect test, patients have that answer. The test is a simple blood draw and detects the presence of AR-V7 protein in circulating tumor cells (CTCs) that cause AR-drugs to be significantly less effective compared to traditional chemotherapy. If AR-V7 protein is found (a positive test result), the patient is more likely to benefit from switching to chemotherapy. If AR-V7 protein is not found (a negative test result), the patient may benefit from new/additional AR therapy. For all prostate cancer patients, it s important to take an active role in your care. Talk to your doctor. Ask questions. Learn about all your options so you can make the best treatment decision for your cancer. To find out more about the Oncotype DX AR-V7 Nucleus Detect test, visit ¹Xtandi is a registered trademark of Astellas Pharma, Inc. Zytiga is a registered trademark of Johnson and Johnson.

7 For More INFORMATION If you have questions or need additional information, please contact the Patient Advocacy team at Genomic Health: Follow us on social media! facebook.com/genomichealth twitter.com/genomichealth youtube.com/genomichealth GHI60023_0918